Literature DB >> 16159946

Fas (CD95)-related apoptosis and rheumatoid arthritis.

S L Peng1.   

Abstract

Abnormal proliferation and/or persistence of synoviocytes and inflammatory cells has long been described in inflammatory arthritis conditions, but only relatively recently has substantial attention been drawn to the relevance of abnormal apoptotic processes in disease pathogenesis and treatment. This review summarizes a current understanding of the Fas (CD95)-Fas ligand (CD178) apoptotic system, which has most predominantly been examined in rheumatoid arthritis. There, synovial inflammation is often characterized by a unique resistance to Fas-related apoptosis, and agonistic therapeutic interventions upon Fas have consistently been found beneficial in both animal and human disease models. Therefore, modulation of the Fas pathway will hopefully be of both pathogenic and therapeutic interest in the study of inflammatory arthritis conditions in general.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159946     DOI: 10.1093/rheumatology/kei113

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  22 in total

1.  Anti-arthritic effects of FasL gene transferred intra-articularly by an inducible lentiviral vector containing improved tet-on system.

Authors:  Qingyu Shi; Xuebi Tian; Yinlin Zhao; Huiyu Luo; Yuke Tian; Ailin Luo
Journal:  Rheumatol Int       Date:  2011-07-27       Impact factor: 2.631

2.  Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis.

Authors:  Bon-A Cho; Ji Hyun Sim; Ji Ah Park; Hye Won Kim; Wan-Hee Yoo; Seung-Hyun Lee; Dong-Sup Lee; Jae Seung Kang; Young-Il Hwang; Wang Jae Lee; Insoo Kang; Eun Bong Lee; Hang-Rae Kim
Journal:  J Clin Immunol       Date:  2012-02-25       Impact factor: 8.317

3.  Multi-compartmental vaccine delivery system for enhanced immune response to gp100 peptide antigen in melanoma immunotherapy.

Authors:  Mayurkumar Kalariya; Srinivas Ganta; Mansoor Amiji
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

4.  Role of cytolytic impairment of natural killer and natural killer T-cell populations in rheumatoid arthritis.

Authors:  Ashish Aggarwal; Aman Sharma; Archana Bhatnagar
Journal:  Clin Rheumatol       Date:  2014-05-07       Impact factor: 2.980

Review 5.  Targeting Fas in osteoresorptive disorders.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Ana Marusic
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

6.  Increased autophagy in CD4+ T cells of rheumatoid arthritis patients results in T-cell hyperactivation and apoptosis resistance.

Authors:  Jorg van Loosdregt; Maura Rossetti; Roberto Spreafico; Maryam Moshref; Merissa Olmer; Gary W Williams; Pavanish Kumar; Dana Copeland; Ken Pischel; Martin Lotz; Salvatore Albani
Journal:  Eur J Immunol       Date:  2016-10-05       Impact factor: 5.532

7.  Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage.

Authors:  Samuel García; Myriam Liz; Juan J Gómez-Reino; Carmen Conde
Journal:  Arthritis Res Ther       Date:  2010-02-26       Impact factor: 5.156

8.  Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity.

Authors:  Thomas D Cunningham; Xinguo Jiang; David J Shapiro
Journal:  Cell Immunol       Date:  2007-05-08       Impact factor: 4.868

9.  Association of systemic and intra-articular osteoclastogenic potential, pro-inflammatory mediators and disease activity with the form of inflammatory arthritis.

Authors:  Marina Ikić; Zrinka Jajić; Elvira Lazić; Sanja Ivčević; Frane Grubišić; Ana Marušić; Nataša Kovačić; Danka Grčević
Journal:  Int Orthop       Date:  2013-10-08       Impact factor: 3.075

10.  Resistance to activation-induced cell death and elevated FLIPL expression of CD4+ T cells in a polyI:C-induced primary biliary cirrhosis mouse model.

Authors:  Tingwang Jiang; Zhijun Han; Sunxiao Chen; Chuanyong Wu; Yujie Tang; Cheng Qian; Yan Chen; Ye Zhou; Ye Zhu; Mingli Gu; Liang Zhu; Dingkang Yao; Anmei Deng; Renqian Zhong
Journal:  Clin Exp Med       Date:  2009-05-06       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.